Literature DB >> 1097448

Myelodysplastics--fate of those followed for twenty years or more.

G A Barden, L C Meyer, F H Stelling.   

Abstract

Of a total of 143 myelodysplastic patients treated between 1928 and 1951, there were sixty-three patients with severe myelodysplasia whose records allowed long-term review. At the time of writing twenty-nine were alive and were twenty to forty-three years old. All were walking in the hospital while under an intensive physical therapy program. However only two of the nine with twelfth thoracic-second lumbar function were walking at final follow-up as adults, while nineteen of the twenty with function at the third lumbar level were doing so. The status of the hips did not correlate with the ability to walk. One-third of the survivors were self-supporting at the time of writing. About one-half had scoliosis and in one-third was greater than 20 degrees.

Entities:  

Mesh:

Year:  1975        PMID: 1097448

Source DB:  PubMed          Journal:  J Bone Joint Surg Am        ISSN: 0021-9355            Impact factor:   5.284


  5 in total

1.  The operative treatment of spinal deformities in MMC.

Authors:  C Hopf; M Schwarz; A Wackerhagen; D Voth
Journal:  Neurosurg Rev       Date:  1993       Impact factor: 3.042

2.  Development of scoliosis in myelomeningocele. Differences in the history caused by idiopathic pattern.

Authors:  P Eysel; C Hopf; M Schwarz; D Voth
Journal:  Neurosurg Rev       Date:  1993       Impact factor: 3.042

3.  Orthopedic management of spina bifida. Part I: hip, knee, and rotational deformities.

Authors:  Vineeta T Swaroop; Luciano Dias
Journal:  J Child Orthop       Date:  2009-10-25       Impact factor: 1.548

Review 4.  Surgical Management of Hip Problems in Myelomeningocele: A Review Article.

Authors:  Taghi Baghdadi; Reza Abdi; Ramin Zargar Bashi; Hossein Aslani
Journal:  Arch Bone Jt Surg       Date:  2016-06

Review 5.  Upper and lower urinary tract outcomes in adult myelomeningocele patients: a systematic review.

Authors:  Paul W Veenboer; J L H Ruud Bosch; Floris W A van Asbeck; Laetitia M O de Kort
Journal:  PLoS One       Date:  2012-10-31       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.